Sequencing Vemurafenib, Cobimetinib, and Atezolizumab for Patients With High-Risk Melanoma
Source: Oncology Learning Network, July 2024
Paolo Ascierto, MD, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy, discusses primary results from the phase 2 NEO-TIM trial which sought to determine the optimal sequencing of vemurafenib, cobimetinib, and atezolizumab among patients with patients with high-risk melanoma.
